周仲国

主任医师、主诊教授 ；医学博士、博士研究生导师、教学督导 

科研方向： 肝癌免疫微环境及耐药研究，肝癌影像组学相关探索

联系方式：zhouzhg@sysucc.org.cn 

一、教育背景及学术任职 

中国抗癌协会青年理事会 常务理事 广东省器官医学与技术学会肝癌综合治疗专委会 主任委员

二、近3年主持科研项目

1.国家自然科学基金面上项目，癌基因TESC诱导钙网蛋白膜转位介导肝癌免疫治疗抵抗的机制研究，2025-01至2028-12，70万，主持

2.广东省自然科学基金面上项目，TESC调控钙网蛋白膜转位诱导肝癌免疫逃逸的机制研究，2024-01至2027-12，15万，主持

3.北京科创医学发展基金会, 重点项目, KC2023-JX-0186-FZ101, PIM2 增敏肝癌灌注化疗联合免疫治疗效果的机制研究, 2024-01 至 2026-12, 15万元, 主持

三、近3年第一/通讯作者文章 

1. Zhikai Zheng; Jiongliang Wang; Tianqing Wu; Minrui He; Yangxun Pan; Juncheng Wang; Jinbin Chen; Dandan Hu; Li Xu; Yaojun Zhang;Minshan Chen; Zhongguo. Hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a retrospective cohort study ,Int J Surg. 2024.10.
2. Kai Li，Jiayu Zhang，Haiwen Lyu，Jinneng Yang，Wenxia Wei，Yuzhi Wang，Haidan Luo，YijingZhang，Xin Jiang，Hairong Yi，Mengan Wang，Caiyun Zhang，Kang Wu，Lishi Xiao， Weijie Wen，Hui Xu，Guolin Li，Yunle Wan，Fang Yang，Runxiang Yang，Xinhui Fu，BaifuQin,Zhongguo Zhou，Haipeng Zhang，Mong-Hong Lee. CSN6-SPOP-HMGCS1 Axis Promotes Hepatocellular Carcinoma Progression via YAP1 Activation. Adv Sci，2024，Apr
3. Ling YH, Liu MN, Yin YX, Zhou ZG, Chen JW, Wei W, Yun JP, Xie D, Guo RP, Cai MY. Integrated genetic and epigenetic analysis reveals DNA repair alterations in multifocal hepatocellular carcinoma. Signal Transduct Target Ther. 2023 Jun 23;8(1):244. doi: 10.1038/s41392-023-01446-z.
4. Wang JC, Chen DP, Lu SX, Chen JB, Wei Y, Liu XC, Tang YH, Zhang R, Chen JC, Kan A, Xu L, Zhang YJ, Hou J, Kuang DM, Chen MS, Zhou ZG. PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma. Cancer Res. 2022 Sep 16;82(18):3307-3320. doi: 10.1158/0008-5472.CAN-21-3899.
5. Ma WJ, Chen Y, Peng JH, Tang C, Zhang L, Liu M, Hu S, Xu H, Tan H, Gu Y, Pan ZZ, Chen G, Zhou ZG, Zhang RX. Stage IV colon cancer patients without DENND2D expression benefit more from neoadjuvant chemotherapy. Cell Death Dis. 2022 May 6;13(5):439. doi: 10.1038/s41419-022-04885-8.
6. Hu Z, Zeng H, Hou J, Wang J, Xu L, Zhang Y, Chen M, Zhou Z. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation. Viruses. 2022 Mar 22;14(4):656. doi: 10.3390/v14040656.
7. Wang XH, Hu ZL, Fu YZ, Hou JY, Li WX, Zhang YJ, Xu L, Zhou QF, Chen MS, Zhou ZG. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. J Gastroenterol. 2022 Mar;57(3):185-198. doi: 10.1007/s00535-022-01855-x.
8. Wang XH, Liu QB, Xiang CL, Mao XH, Yang B, Li Q, Zhou QF, Li SQ, Zhou ZG, Chen MS. Multi-institutional validation of novel models for predicting the prognosis of patients with huge hepatocellular carcinoma. Int J Cancer. 2021 Jul 1;149(1):127-138. doi: 10.1002/ijc.33516.